Dermatophytosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 117: | Line 117: | ||
* Widespread Tinea pedis of the sole, heel, or dorsum of the foot or when there is blistering. | * Widespread Tinea pedis of the sole, heel, or dorsum of the foot or when there is blistering. | ||
==== Common drugs ==== | ==== Common oral drugs ==== | ||
{| class="wikitable" | {| class="wikitable" | ||
!Condition | !Condition | ||
Line 158: | Line 158: | ||
|4-8 weeks | |4-8 weeks | ||
|} | |} | ||
==== Newer oral drugs ==== | |||
* Recently, posoconazole was found to be effective in a patient with extensive dermatophytic skin and nail infection with underlying CARD9 mutation. | |||
==References== | ==References== |
Revision as of 18:45, 29 June 2017
Dermatophytosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dermatophytosis medical therapy On the Web |
American Roentgen Ray Society Images of Dermatophytosis medical therapy |
Risk calculators and risk factors for Dermatophytosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Topical antifungals
Azoles | Preparation | Infection site | Application frequency | Duration of treatment |
---|---|---|---|---|
Clotrimazole | Cream, lotion | T. corporis/cruris/pedis | BD | 4-6 weeks |
Econazole | Cream | T. corporis/cruris/pedis | OD-BD | 4-6 weeks |
Miconazole | Cream, lotion | T. corporis/cruris/pedis | BD | 4-6 weeks |
Oxiconazole | Cream, lotion | T. corporis/cruris/pedis | OD-BD | 4 weeks |
Sertaconazole | Cream | T. corporis/cruris/pedis | BD | 4 weeks |
Luliconazole | Cream, lotion | T. corporis/cruris/pedis | OD | 2 weeks |
Eberconazole | Cream | T. corporis/cruris/pedis | OD | 2-4 weeks |
Efinaconazole | Solution | T. pedis | OD | Up to 52 weeks |
Terbinafine | Cream, powder | T. corporis | BD | 2 weeks |
T. cruris | BD | 2 weeks | ||
T. pedis | BD | 4 weeks | ||
T. manum | BD | 4 weeks | ||
Naftifine 1% | Cream | T. corporis/cruris/pedis | OD-BD | 2 weeks beyond symptom resolution |
Butenafine 1% | Cream | T. corporis/cruris/pedis | OD-BD | 2-4 weeks |
Amolorfine 0.25% | Cream | T. corporis | BD | 4 weeks |
Amphotericin B 1mg | Lipid based gel | T. corporis | BD | 2 weeks |
Systemic antifungals
Indications of systemic antifungal therapy in dermatophytosis
The following are the situations where systemic antifungal therapy may be preferred
- Tinea capitis.
- Onychomycosis.
- Tinea affecting more than one body part simultaneously, for example, tinea cruris and corporis, or tinea cruris and tinea pedis
- Widespread Tinea corporis.
- Widespread Tinea pedis of the sole, heel, or dorsum of the foot or when there is blistering.
Common oral drugs
Condition | Drug | Dosage | Duration |
---|---|---|---|
T. corporis/cruris | Terbinafine | 250 mg OD (3-6mg/kg/day) | 2-3 weeks |
Itraconazole | 200 mg/day | 1-2 weeks | |
Fluconazole | 150-300mg/week | 3-4 weeks | |
Griseofulvin | 500 mg/day (10-20mg/kg/day) | 2-4 weeks | |
T. pedis | Terbinafine | 250mg OD | 1 week |
Itraconazole | 100-200 mg/day | 2-4 weeks | |
Fluconazole | 150 mg/weel | 4 weeks | |
Griseofulvin | 750-1000 mg/day | 4-8 weeks |
Newer oral drugs
- Recently, posoconazole was found to be effective in a patient with extensive dermatophytic skin and nail infection with underlying CARD9 mutation.